Recent advances in the diagnosis and management of acute myocardial infarction

Yi-Keng Hsieh; Mei-Tzu Wang; Chien-Ying Wang; Cheng-Fong Chen; Yu-Ling Ko; Wei-Chun Huang

doi:10.1097/JCMA.0000000000001001

Recent advances in the diagnosis and management of acute myocardial infarction

J Chin Med Assoc. 2023 Nov 1;86(11):950-959. doi: 10.1097/JCMA.0000000000001001. Epub 2023 Oct 6.

Authors

Yi-Keng Hsieh^{1

2

3}, Mei-Tzu Wang^{1

3}, Chien-Ying Wang^{3

4

5

6}, Cheng-Fong Chen^{7

8

6}, Yu-Ling Ko⁹, Wei-Chun Huang^{1

2

10}

Affiliations

¹ Department of Critical Care Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC.
² Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC.
³ School of Medicine, National Yang Ming Chao Tung University, Taipei, Taiwan, ROC.
⁴ Department of Critical Care Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
⁵ Division of Trauma, Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
⁶ Department of Exercise and Health Sciences, University of Taipei, Taipei, Taiwan, ROC.
⁷ Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
⁸ Department of Surgery, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
⁹ Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
¹⁰ Department of Physical Therapy, Fooyin University, Kaohsiung, Taiwan, ROC.

PMID: 37801590
DOI: 10.1097/JCMA.0000000000001001

Abstract

With the discovery of new biomarkers for the early detection of acute myocardial infarction (AMI), advancements in valid medication, and percutaneous coronary intervention (PCI), the overall prognosis of AMI has improved remarkably. Nevertheless, challenges remain which require more difficult work to overcome. Novel diagnostic and therapeutic techniques include new AMI biomarkers, hypothermia therapy, supersaturated oxygen (SSO 2 ) therapy, targeted anti-inflammatory therapy, targeted angiogenesis therapy, and stem cell therapy. With these novel methods, we believe that the infarction size after AMI will decrease, and myocardial injury-associated ventricular remodeling may be avoided. This review focuses on novel advances in the diagnosis and management of AMI.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Humans
Myocardial Infarction*
Percutaneous Coronary Intervention*
Prognosis
Treatment Outcome

Substances

Biomarkers